
Switching Virologically Suppressed HIV Patients: Signals, Switch Rates, and Resistance
Switch rates remain below 20%, and the panel debates whether that reflects stable patients or clinical complacency, while stressing that resistance history must anchor every switch decision.
Episodes in this series

In "Switching Virologically Suppressed HIV Patients: Signals, Switch Rates, and Resistance," the panel turns to patients who are doing well on paper but may still warrant a change.
Dr. Burkhart explains that the ideal time to switch is while a patient is virologically suppressed. Guidelines support a switch when there is a clear therapeutic benefit and future treatment options are not compromised. Benefits may include resolving side effects, pill fatigue, or adverse events. Other triggers include a newly added interacting medication or a pregnancy requiring a different regimen.
Dr. Madison notes that switch rates have been reported below 20%. Dr. Burkhart says there may not be an ideal number, since many patients are stable and feeling fine. The risk is complacency, and clinicians have a duty to tell patients about newer options. Dr. Madison warns against an "if it ain't broke, don't fix it" mindset. Too often, patients hear about new drugs elsewhere and raise them in clinic first.
Dr. Durham says his clinic sees relatively few switches, partly because most patients already use newer recommended regimens. He describes patients who have long tolerated older efavirenz-based therapy but fear losing control by switching. His approach is to present newer, potentially better options and at least have the conversation. Dr. Astle compares the decision to cardiovascular disease and diabetes management. A new class alone is not reason to switch; the question is what actual benefit the patient gains. Dr. Nguyen shares a patient who reacted to injectable cabotegravir and switched successfully to a different regimen. She notes the reverse is also true, since some long-term patients resist any change.
Turning to resistance, Dr. Burkhart calls it one of the most important factors in any switch. Previous resistance never goes away, so the full treatment history must be reviewed. Switching into a regimen with existing resistance could compromise future options. The panel also stresses baseline genotypic testing at diagnosis, especially before moving from a three-drug to a two-drug regimen.
Up next, in "HIV Adherence vs Regimen Change: Lived Experience and Hidden Drug Interactions," Dr. Astle and Dr. Durham separate adherence problems from true regimen failure and share a memorable interaction case.
Funding supported by Gilead. Content independently developed by Pharmacy Times.
Related to this article








